MoneyWorks4Me

Sun Pharmaceutical Industries informs about press release

16 Mar 2026 Evaluate

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1786.40
Dr. Reddys Labs. 1197.40
Cipla 1335.05
Lupin 2012.10
Zydus Lifesciences 1143.50
View more..